No connection

Search Results

GDTC vs JNJ

GDTC
CytoMed Therapeutics Limited
BEARISH
Price
$1.00
Market Cap
$11.8M
Sector
Healthcare
AI Confidence
85%
JNJ
Johnson & Johnson
NEUTRAL
Price
$237.96
Market Cap
$573.46B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
GDTC
--
JNJ
21.55
Forward P/E
GDTC
-6.67
JNJ
18.9
P/B Ratio
GDTC
2.31
JNJ
7.03
P/S Ratio
GDTC
13.74
JNJ
6.09
EV/EBITDA
GDTC
-2.73
JNJ
17.81

Profitability

Gross Margin
GDTC
89.57%
JNJ
68.08%
Operating Margin
GDTC
-535.25%
JNJ
23.97%
Profit Margin
GDTC
0.0%
JNJ
28.46%
ROE
GDTC
-50.28%
JNJ
35.03%
ROA
GDTC
-29.31%
JNJ
8.68%

Growth

Revenue Growth
GDTC
46.9%
JNJ
9.1%
Earnings Growth
GDTC
--
JNJ
48.6%

Financial Health

Debt/Equity
GDTC
0.07
JNJ
0.6
Current Ratio
GDTC
5.17
JNJ
1.03
Quick Ratio
GDTC
3.14
JNJ
0.69

Dividends

Dividend Yield
GDTC
--
JNJ
2.19%
Payout Ratio
GDTC
0.0%
JNJ
46.6%

AI Verdict

GDTC BEARISH

GDTC exhibits a fragile financial profile characterized by a Piotroski F-Score of 4/9, placing it in the 'stable' but lower-tier health category. While the company maintains strong liquidity (Current Ratio 5.17) and very low debt, these are overshadowed by a catastrophic operating margin of -535.25% and a total lack of profitability. The technical trend is severely bearish (0/100), with the stock price having declined over 63% in the last year and 75% over five years. Despite positive revenue growth, the valuation remains disconnected from fundamentals, trading at a high Price/Sales ratio of 13.74 without a path to earnings.

Strengths
Strong liquidity position with a Current Ratio of 5.17
Very low leverage (Debt/Equity of 0.07)
High Gross Margin (89.57%) typical of high-potential biotech
Risks
Extreme operational inefficiency with an operating margin of -535.25%
Severe multi-year price erosion (-75% over 3-5 years)
Micro-cap volatility and lack of institutional analyst coverage
JNJ NEUTRAL

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.

Strengths
Exceptional Return on Equity (ROE) of 35.03%
Strong profit margins (28.46%) and gross margins (68.08%)
Consistent earnings beat track record over 25 quarters
Risks
Weak Piotroski F-Score (3/9) indicating declining fundamental health
Bearish insider activity with $58.35M in net sales and zero buys
Low liquidity indicated by a Quick Ratio of 0.69

Compare Another Pair

GDTC vs JNJ: Head-to-Head Comparison

This page compares CytoMed Therapeutics Limited (GDTC) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile